Brief Communication
Factor VII, encoded by the F7 gene, is a vitamin K-dependent glycoprotein that participates in the blood coagulation cascade. Clotting disorders attributed to factor VII deficiency have been identified in several breeds of dog, including Beagles, 1, 2, 9, 14, 16 Alaskan Malamutes, 8 Alaskan Klee Kai dogs, 4 and others. 3, 7 Canine inherited factor VII deficiency is an autosomal recessive condition caused by a G to A missense mutation in the F7 gene, resulting in substitution of glycine 96 by glutamic acid in exon 5. 1 This amino acid change results in mild-to-moderate bleeding in these dogs, with postsurgical hemorrhage in most dogs without prior history of spontaneous bleeding. 1 Unlike more serious coagulopathies, such as type 3 von Willebrand disease in which dogs have a history of impaired hemostasis, owners and veterinarians have no reason to expect postsurgical complications in dogs with factor VII deficiency. 1, 15 A phenotypic diagnosis can be made based on increased prothrombin time (PT), defined as any value greater than the valid upper reference limit of the laboratory performing the testing, in conjunction with a normal activated partial thromboplastin time (aPTT). 1, 15 Without genetic testing for factor VII deficiency, other differential diagnoses, such as the early stages of hepatic disease or anticoagulant rodenticide exposure, cannot be ruled out. 15 Additionally, given that coagulation times can vary among affected dogs, and carriers would be normal with these clinical assays, a molecular genetic test that can accurately identify both the heterozygous and the homozygous mutant individuals is more useful for dog breeders. Genetic testing laboratories recognize that the presence of a common mutation in multiple breeds of dog is amenable to the development of a single, reliable test for factor VII deficiency across many breeds.
Initial identification of the factor VII deficiency mutation was achieved by direct sequencing of the F7 gene in an affected Beagle; additional dogs were screened by using a restriction digest run on polyacrylamide gel. 1 For laboratory assays, robust tests can be developed to directly interrogate the mutation site and distinguish wild-type alleles from mutant alleles. For example, a PCR-based assay was developed in which the digested PCR products were visualized on agarose gel. 2 This method was simpler than an earlier method, 1 and was used to screen a large colony of dogs for heterozygous and homozygous mutant individuals. In our laboratory, we utilized in-house, primer-prediction software to identify primers that flanked the F7 mutation at chr22:60,578,895 (CanFam3.1) and developed 2 routine genotyping methods to be used as assays, in keeping with our internal proficiency quality assurance protocols. [10] [11] [12] From February 2015 through November 2017, we tested DNA extracted from buccal swabs via routine methods 12 from 43 Beagles using our 2 assays for factor VII deficiency. We identified 11 homozygous normal dogs, 12 heterozygous (carrier) dogs, and 20 homozygous mutant (at-risk/affected) dogs. In November 2017, we were contacted by a client who received 5 homozygous mutant (at-risk/affected) results and 2 heterozygous (carrier) results for a litter of 7 puppies, although the dam and sire were tested at another laboratory and genotyped as homozygous mutant and homozygous normal, respectively. Such a breeding should only produce heterozygous carrier puppies. Based on our internal protocol for investigating discrepant results, we performed a parentage analysis between the offspring in question, the homozygous mutant dam, and the homozygous normal sire. The parentage analysis confirmed the homozygous normal dog to be the sire (data not shown). To investigate further, DNA samples from the 5 offspring, the dam, and the sire were sent for sequencing of the region of the F7 gene encompassing the primers used for our F7 assays (Macrogen USA, Rockville, MD; Fig. 1 ). Sequencing identified an intronic C>T variant at site chr22:60,578,848 that sits under the annealing site of the forward primer used in our original PCR assays as well as the forward primer described elsewhere 2 ( Table 1 ). The sire is heterozygous for this variant, and all 5 puppies originally genotyped as homozygous mutant are also heterozygous. Presumably, this polymorphism caused allele dropout (nonamplification) of the normal, paternally inherited allele.
The discovery of this polymorphism located within our forward primers for both genotyping assays prompted us to develop new primer pairs outside of this region to avoid possible allele dropout. The new primer pairs (Table 1 , Fig. 1 ) were used to rescreen 36 Beagles that were previously reported as homozygous normal or homozygous mutant by our laboratory and therefore had the potential to have been misclassified because of allele dropout. After retesting, 7 Beagles were reclassified from homozygous mutant (at-risk /affected) to heterozygous (carriers). Five of these were the original puppies that we sequenced and 2 were unrelated Beagles from 2 different owners.
Additional targeted sequencing was performed on 429 dogs of various breeds (MiSeq system, Illumina, San Diego, CA) using primers shown in Table 1 . Raw sequences were aligned using BWA-MEM, and regions of interest were examined using SAMtools. 6 Sequence data revealed an adjacent C>T polymorphism at chr22:60,578,849 that was not found in the Beagles studied (Table 2) . Of 429 dogs screened, 90 were found to carry one or both of the C>T polymorphisms. The chr22:60,578,848 polymorphism identified in the Beagle was also identified in 69 individuals from 18 other breeds. Among these, 56 were heterozygous and 13 were homozygous. The chr22:60,578,849 polymorphism was identified in 19 individuals from 15 breeds. Among Yellow indicates new primer pairs for assay 2. Blue and yellow primers were also used for direct sequencing as indicated in Table 1 . these, 17 were heterozygous and 2 were homozygous. Finally, 2 additional individuals from different breeds were heterozygotes for both polymorphisms. Although these polymorphisms were found in 27 breeds, most of the breeds are not known to carry the mutation associated with factor VII deficiency. However, the chr22:60,578,849 C>T polymorphism was identified in the Giant Schnauzer, which is a breed that carries the disease-associated G>A missense mutation in F7. Thirteen Giant Schnauzers previously tested for the F7 mutation were retested with the new primer sets and all were homozygous normal, as originally reported to clients. We developed our own internal proficiency program that includes 2 independent testing methods for each disease or trait test offered in our laboratory. 10 Although we cannot completely eliminate the risk of allele dropout, this program allows us to recognize potential allele dropout by comparing genotyping results across testing platforms. Because predicting every polymorphism in the canine genome is impossible, comparing results across methods within an individual sample can help ensure that normal genomic variation is less likely to affect target amplification. However, an essential component to this program is the use of minimal or nonoverlapping primers between the 2 methods. In the case presented herein, we failed to recognize that the 2 genotyping methods that we were using for the F7 mutation had significant overlapping primers that, unfortunately, also overlapped an apparently, relatively frequent polymorphism in the Beagle population. This led to reporting errors and significant time and cost involved in correcting the assays and regaining the trust of our clients.
Because genetic testing is relatively simple, quick, and affordable, its use is increasing and can provide additional information to aid in decisions regarding breeding, as well as diagnosis and treatment of other genetic disorders. The importance of assay development that minimizes allele dropout is crucial to accurate testing. Although it is impossible to completely avoid all sites of polymorphism during primer development, laboratories can reduce the chance of developing primers overlapping regions of polymorphism by screening repositories that contain this information, such as the Database of Single Nucleotide Polymorphisms (dbSNP) and European Bioinformatics Institute (EMBL-EBI) databases. 5, 13 The dbSNP was a repository for non-human mam- Laboratories should be committed to the highest accuracy possible and develop safeguards, including multiple independent assays, to prevent and clarify discrepant results. 10 Additionally, laboratories should work with clients to understand whether any discrepancies reflect true biology, as in our case, non-paternity, or sample mishandling by either the client or the laboratory. Because veterinary genetic testing laboratories are not, to date, required to be accredited, and have no regulatory oversight, it is up to individual laboratories to implement systems and protocols to minimize errors. We recognize that genetic testing results are used to make breeding decisions and sometime irreversible decisions, such as neutering or euthanasia. As such, for every mutation for which we offer testing, we chose to implement an on-going methods-based proficiency testing program. 10 This testing program includes interrogating every mutation region utilizing 2 independent methods regardless of the genotypes and is applied across all samples, not just when heterozygous or at-risk results are obtained. To prevent the future development of primers overlapping areas with known polymorphisms, SNP databases such as dbSNP and EMBL-EBI should be reviewed during the development of primers, and any new genetic variants should be submitted to public SNP databases such as EMBL-EBI European Variation Archive (https://www.ebi.ac.uk/eva/?Home). Additionally, there should be collaboration among genetic testing laboratories to share the identification of polymorphic variants or other technical issues that may impact ongoing test performance, because the ultimate goal of all testing laboratories is to provide accurate genetic results and thereby improve the health of dogs.
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